Videos

Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies

Dr. Patrick Borgen, from the Maimonides Breast Cancer Center, Discusses the Negative Effects of Pinkwashing

Contrary to earlier findings, surgical breast biopsies may not be as overused as previously thought, according to a recent study published in the Journal of the American College of Radiology.

Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention

Recognition of breast cancer subtypes and research into their underlying biologies is driving the development of new therapies.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer

Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.

The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.

Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Dr. Harold Harvey from Penn State Hershey Cancer Institute Discusses Preventing Breast Cancer

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

This commentary will highlight 2 phase III randomized trials and a retrospective review of a large national database that has been strongly criticized based on its overall conclusions.

New data show that roughly one-fifth of tamoxifen-treated male patients with breast cancer stop treatment early because of side effects.

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

The use of a navigation program for an urban safety net breast cancer population has only a moderate effect on the time from symptom presentation to treatment.